Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Decisions of the Annual General Meeting September 16, 2020 at 3:30 pm local time (EET).

Read more

The usefulness of Biohit GastroPanel® biomarkers in diagnosis of atrophic gastritis confirmed in a multi-center study in France

Read more

Biohit Group’s Net Sales outlook for 2020 changed

The coronavirus (2019-nCoV) has impacted negatively on the demand of the company’s products globally and due to that Biohit Group’s Net Sales outlook for 2020 has changed.

Read more

Does an undiagnosed atrophic gastritis (acid-free stomach) increase the risk of coronavirus infection, its complications and mortality particularly among elderly people?

Read more

Coronavirus Information

Dear Partner, 

At this time of global struggle against the coronavirus, Biohit Oyj strives to ensure that our employee´s and partners remain healthy. We have already taken several actions in accordance with guidelines of the Finnish government authorities, incl. allowing office workers to work solely from home.  

At the time of writing, there have been no disruptions to kit production. Our factory remains open and we are serving our customers as best as we can. There are certain challenges related to air freight (e.g. airlines have cancelled many flights) and this can manifest in higher freight charges or longer transport duration.  

Please contact our Customer Services ( for the latest information regarding the handling of your order. 

Additional information 
CEO Semi Korpela, Biohit Oyj 
tel. +358 9 773 861 

Biohit in brief 

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit’s Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.